Vascular Endothelial Growth Factor as a Determinant of Diabetic Nephropathy

[1]  D. Suzuki,et al.  Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  M. Cooper,et al.  Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin–angiotensin system , 2005, Journal of hypertension.

[3]  K. Choi,et al.  Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. , 2005, Kidney international.

[4]  G. Lip,et al.  Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. , 2004, Diabetes care.

[5]  A. Flyvbjerg,et al.  From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. , 2004, Endocrine reviews.

[6]  M. Cooper,et al.  Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. , 2004, Diabetes.

[7]  F. Ziyadeh,et al.  Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor-beta1 in mouse podocytes. , 2004, Diabetes.

[8]  D. Cha,et al.  Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. , 2004, The Journal of endocrinology.

[9]  S. Chakrabarti,et al.  Vascular endothelial growth factor in diabetes induced early retinal abnormalities. , 2004, Diabetes research and clinical practice.

[10]  H. Haller,et al.  Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. , 2004, Diabetes.

[11]  T. Kato,et al.  Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[12]  A. Flyvbjerg,et al.  The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. , 2004, Kidney international.

[13]  Geoffrey C Gurtner,et al.  Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. , 2004, The American journal of pathology.

[14]  D. Cha,et al.  Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[15]  G. Gambaro,et al.  Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. , 2004, European journal of endocrinology.

[16]  Xiao-Feng Sun,et al.  Neonatal losartan treatment suppresses renal expression of molecules involved in cell-cell and cell-matrix interactions. , 2004, Journal of the American Society of Nephrology : JASN.

[17]  S. Kishi,et al.  Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. , 2004, Ophthalmology.

[18]  A. Gabriele,et al.  The impairment of renal function is not associated to altered circulating vascular endothelial growth factor in patients with Type 2 diabetes and hypertension. , 2004, Diabetes, nutrition & metabolism.

[19]  H. Baelde,et al.  Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  R. Østerby,et al.  No nephropathy in Type 2 diabetic patient with POEMS syndrome with an elevated plasma VEGF , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[21]  P. Brenchley,et al.  Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. , 2004, Diabetes.

[22]  D. Mukhopadhyay,et al.  Role of Insulin Receptor Substrates and Protein Kinase C-ζ in Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Pancreatic Cancer Cells* , 2004, Journal of Biological Chemistry.

[23]  M. Cooper,et al.  Retinal Expression of Vascular Endothelial Growth Factor Is Mediated by Angiotensin Type 1 and Type 2 Receptors , 2004, Hypertension.

[24]  M. Cooper,et al.  Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. , 2003, Journal of the American Society of Nephrology : JASN.

[25]  H. Gröne,et al.  Vascular Endothelial Growth Factor in Diabetic Nephropathy , 2003, Kidney and Blood Pressure Research.

[26]  M. Bartoli,et al.  Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives , 2003, Diabetes/metabolism research and reviews.

[27]  A. Tobar,et al.  Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease? , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  M. Cooper,et al.  Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. , 2003, The American journal of pathology.

[29]  M. Khamaisi,et al.  The emerging role of VEGF in diabetic kidney disease. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  M. Cooper,et al.  Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. , 2003, Kidney international.

[31]  V. Nicoletti,et al.  Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF). , 2003, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[32]  J. Haigh,et al.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. , 2003, The Journal of clinical investigation.

[33]  S. Midorikawa,et al.  Plasma vascular endothelial growth factor in Japanese Type 2 diabetic patients with and without nephropathy. , 2002, Journal of diabetes and its complications.

[34]  R. Tilton,et al.  Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. , 2002, Diabetes.

[35]  Connie J. Wang,et al.  Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. , 2002, Kidney international.

[36]  R. Kalluri,et al.  Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. , 2002, Kidney international.

[37]  Z. Makita,et al.  Advanced Glycation End Product-induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Human-cultured Mesangial Cells* , 2002, The Journal of Biological Chemistry.

[38]  R. Tilton,et al.  High protein-induced glomerular hypertrophy is vascular endothelial growth factor-dependent. , 2002, Kidney international.

[39]  M. Nagata,et al.  Podocyte Injury Promotes Progressive Nephropathy in Zucker Diabetic Fatty Rats , 2002, Laboratory Investigation.

[40]  N. Ferrara,et al.  The Role of Vascular Endothelial Growth Factor in Angiogenesis , 2002, Acta Haematologica.

[41]  M. Cooper,et al.  Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy , 2001, Diabetologia.

[42]  J. Mandl,et al.  The regulation of the induction of vascular endothelial growth factor at the onset of diabetes in spontaneously diabetic rats. , 2001, Life sciences.

[43]  F. Santilli,et al.  Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. , 2001, The Journal of clinical endocrinology and metabolism.

[44]  R. Tilton,et al.  Antibodies against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experimental Diabetes Materials and Methods Laboratory Animals , 2022 .

[45]  L. Aiello,et al.  Circulating plasma vascular endothelial growth factor and microvascular complications of Type 1 diabetes mellitus: the influence of ACE inhibition , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[46]  F. Fyhrquist,et al.  Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. , 2001, American journal of physiology. Heart and circulatory physiology.

[47]  G. Gambaro,et al.  PROTEINS, GROWTH FACTORS, AND PROGRESSION OF KIDNEY DISEASE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTORS IN DIABETIC NEPHROPATHY: EXPRESSION STUDIES IN BIOPSIES OF TYPE 2 DIABETIC PATIENTS , 2003 .

[48]  G. Remuzzi,et al.  Repairing renal lesions: will VEGF be the builder? , 2000, Kidney international.

[49]  D. Cha,et al.  Role of vascular endothelial growth factor in diabetic nephropathy. , 2000, Kidney international. Supplement.

[50]  F. Cipollone,et al.  Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[51]  W. Jelkmann,et al.  Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. , 2000, Kidney international.

[52]  D. Cha,et al.  Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. , 2000, The Journal of endocrinology.

[53]  H. Parving,et al.  Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. , 2000, Kidney international. Supplement.

[54]  M. Cooper,et al.  Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. , 1999, Diabetes.

[55]  F. Locatelli,et al.  End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[56]  K. Blennow,et al.  The Role of the Polymorphic Genes Apolipoprotein E and Methylene- tetrahydrofolate Reductase in the Development of Dementia of the Alzheimer Type , 1999, Dementia and Geriatric Cognitive Disorders.

[57]  R. Busse,et al.  Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. , 1999, Diabetes.

[58]  Z. Makita,et al.  Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 , 1999, Diabetologia.

[59]  L. Gnudi,et al.  Interaction of Angiotensin Ii and Mechanical Stretch on Vascular Endothelial Growth Factor Production by Human Mesangial Cells , 2022 .

[60]  M. Serio,et al.  Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. , 1999, Journal of the American Society of Nephrology : JASN.

[61]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  M. Cooper,et al.  Pathophysiology of diabetic nephropathy. , 1998, Metabolism: clinical and experimental.

[63]  C. Dafogianni,et al.  Serum Levels of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Children and Adolescents with Type 1 Diabetes Mellitus , 1998, Pediatric Research.

[64]  M. Cooper,et al.  Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[65]  H. Gröne,et al.  Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. , 1998, Journal of the American Society of Nephrology : JASN.

[66]  A. E. El Nahas,et al.  VEGF and diabetic microvascular complications. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[67]  K. Shulman,et al.  Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. , 1996, Journal of the American Society of Nephrology : JASN.

[68]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[69]  B. Williams,et al.  Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. , 1995, Hypertension.

[70]  K. Plate,et al.  Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. , 1995, The American journal of physiology.

[71]  E. Manseau,et al.  Vascular permeability factor mRNA and protein expression in human kidney. , 1992, Kidney international.